Pharmacological management of hyponatremia. (13th August 2018)

• Record Type: Journal Article
• Authors: Filippatos, Theodosios; Elisaf, Moses; Liamis, George
• Is Part Of: Expert opinion on pharmacotherapy. Volume 19:Number 12(2018)
• Page Start: 1337
• Page End: 1344
• Publication Date: 2018-08-13
• Subjects: Hyponatremia -- vaptans -- urea -- demeclocycline -- loop diuretics -- saline; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1080/14656566.2018.1504920
• Languages: English
• ISSNs: 1465-6566

Abstract

ABSTRACT: Introduction : Hyponatremia is the most common electrolyte disorder with a prevalence of up to 30% in hospitalized patients. Furthermore, it is associated with increased morbidity and mortality. Areas covered : This review discusses the efficacy and side effects of the currently available treatment options for hyponatremia and the differences in the pharmacological approach between the European and USA guidelines. Additionally, the authors provide their expert perspectives on current treatment strategies and what they expect from this field in the future. Expert opinion : Several pharmacological options are available for the treatment of hyponatremia, but data from trials examining and comparing these treatments are missing. Regarding chronic hyponatremia, the role of vaptans should be further analyzed, focusing on comparisons with other active treatments on patient-relevant outcomes and not only on serum sodium concentration. Clinicians should be cautious to an overly rapid increase in serum sodium levels with all available treatment strategies. Finally, it is important to ascertain whether correction of serum sodium levels improves mortality in hyponatremic patients.